Metastatic Prostate Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

The metastatic prostate cancer market was valued at approximately USD 7 billion in 2023 across the 7MM and is projected to grow at a robust CAGR during the forecast period (2024–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the metastatic prostate cancer landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The metastatic prostate cancer market is increasingly guided by blockbuster androgen receptor inhibitors and novel PARP inhibitors. XTANDI remains the dominant revenue generator in the prostate cancer market, generating approximately USD 2,800 million in annual sales in 2023, with stable growth since 2021 despite increasing competition. The market is further driven by emerging therapies including NUBEQA (darolutamide), which is rapidly emerging as a rising contender with strong uptake in triplet therapy combinations, and PLUVICTO (lutetium-177 PSMA-617), a radioligand therapy that achieved unexpectedly robust market penetration following its 2022 approval.

DelveInsight's report, "Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the metastatic prostate cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines metastatic prostate cancer market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the metastatic prostate cancer market outlook, drug uptake, treatment scenario and epidemiology trends, visit Metastatic Prostate Cancer Market Forecast

Some of the key facts of the Metastatic Prostate Cancer Market Report:

• Key Metastatic Prostate Cancer Companies: Astellas Pharma, Janssen, Bayer, AstraZeneca, Pfizer, Novartis, Arvinas, MacroGenics, Daiichi Sankyo, Bristol Myers Squibb, Merck, Point Biopharma, Lantheus Holdings, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
• Key Metastatic Prostate Cancer Therapies: XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), NUBEQA (darolutamide), ERLEADA (apalutamide), PLUVICTO (lutetium-177 PSMA-617), AKEEGA (olaparib), TALZENNA (talazoparib), LYNPARZA (olaparib), RUBRACA (rucaparib), ARV-110 (bavdegalutamide), MGC018 (vobramitamab duocarmazine), DS-7300, and others
• The metastatic prostate cancer market is expected to surge due to the rising prevalence of prostate cancer cases resulting from the rapidly aging population and growing disease awareness among people. Furthermore, launching various multiple-stage metastatic prostate cancer pipeline products and extensive market penetration of approved therapies through label expansions will significantly revolutionize the metastatic prostate cancer market dynamics.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is a type of malignancy in the prostate gland, a part of the male reproductive system, that has spread from the prostate to other parts of the body and is sometimes called advanced prostate cancer. It most commonly spreads to lymph nodes in other parts of the body or to the bones and can also spread to other organs such as the lungs. Metastatic hormone-sensitive prostate cancer (mHSPC) is characterized by cancer that has spread beyond the prostate into the body but retains sensitivity to hormone therapy. In contrast, metastatic castration-resistant prostate cancer (mCRPC) represents a stage where the cancer stops responding to hormone treatment despite suppression of testosterone levels, making it an aggressive and challenging disease state. Both disease stages significantly impact patient survival and quality of life, requiring multi-modal treatment approaches. Risk factors include advancing age, genetic predisposition, family history of prostate cancer, racial and ethnic factors, and environmental exposures. Early diagnosis through PSA testing and advanced imaging enables more effective treatment planning and improved patient outcomes.

Key Trends in Metastatic Prostate Cancer Therapeutics Market:

• Rising Adoption of Androgen Receptor Pathway Inhibitors: Increasing use of next-generation androgen receptor inhibitors (apalutamide, enzalutamide, darolutamide) as first-line and subsequent-line therapies for mCRPC and mHSPC.
• PARP Inhibitor Expansion: Growing uptake of PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) in patients with HRR gene mutations (BRCA1/2), with recent FDA approvals in 1L settings.
• Radioligand Therapy Integration: Expanding adoption of PSMA-targeted radioligand therapies such as PLUVICTO in treatment-resistant mCRPC with exceptionally strong market uptake.
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics enabling patient stratification and identification of HRR mutations, AR mutations, and PSMA expression levels.
• Pipeline Innovation: Development of novel mechanisms including PROTAC degraders (ARV-110), B7-H3 ADCs (MGC018, DS-7300), and bispecific antibodies targeting STEAP1 and other prostate cancer-specific antigens.
• Triplet Therapy Paradigm: Shift toward combination therapies such as NUBEQA plus ADT and chemotherapy as new standard of care for mHSPC patients.

Metastatic Prostate Cancer Epidemiology

The report on metastatic prostate cancer epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease severity patterns stratified by disease stage and disease status. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of metastatic prostate cancer and plan targeted interventions, research, and treatment strategies.

Metastatic Prostate Cancer Epidemiology Segmentation:

The metastatic prostate cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Prostate Cancer in the 7MM
• Total Diagnosed Prevalent Cases of Prostate Cancer in the 7MM
• Age-specific Cases of Prostate cancer in the 7MM
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM
• Total Metastatic Cases of Prostate Cancer in the 7MM
• Total Treated Cases of mCRPC in the 7MM
• Total Treated Cases of mCSPC/mHSPC in the 7MM

Download the report to understand which factors are driving metastatic prostate cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

Recent Developments In The Metastatic Prostate Cancer Treatment Landscape:

• In July 2025, the European Commission approved NUBEQA™ (darolutamide), an oral androgen receptor inhibitor, in combination with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). The approval was based on Phase III ARANOTE trial results demonstrating a 46% reduction in risk of radiological progression or death versus placebo plus ADT.
• In February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-powered in vitro diagnostic device that generates heatmaps to identify small and rare missed prostatic cancers, providing pathologists with a safety net for accurate diagnoses.
• In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® combined with atezolizumab in mCRPC showed non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
• In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for LYNPARZA® in BRCA-mutated mCRPC, enabling better patient stratification.
• In July 2024, the ARANOTE trial demonstrated that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
• In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC), accelerating its development timeline.
• In June 2024, Kangpu Biopharmaceuticals received FDA approval to initiate a Phase II/III trial of KPG-121 combined with abiraterone for mCRPC.
• In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients, expanding the radioligand therapy landscape.
• In April 2024, Astellas Pharma received European approval for XTANDI™ (enzalutamide) in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC), expanding the label.
• In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC, demonstrating preliminary efficacy.

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential metastatic prostate cancer drugs expected to be launched in the market during 2024–2034. The analysis covers metastatic prostate cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. The mCRPC market has experienced strong uptake of XTANDI, ZYTIGA, and ERLEADA, with XTANDI maintaining dominant market position. PLUVICTO has achieved unexpectedly robust uptake in the third-line mCRPC setting since 2022 approval. Point Biopharma's PSMA [Lu-177]-PNT2002 is expected to achieve medium-fast uptake, though PLUVICTO's approval has intensified competitive pressure. ARV-110 is anticipated to achieve medium-fast uptake with launch expected by 2025, though efficacy may be limited to patients with specific AR T878 and H875 mutations.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal use. Additionally, it compares the drugs based on market share and identifies therapeutic classes with greatest commercial potential.

The report also covers metastatic prostate cancer pipeline development activities, providing valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It analyzes recent developments including collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.

Metastatic Prostate Cancer Therapies and Key Companies

• XTANDI (enzalutamide): Astellas Pharma / Pfizer
• ZYTIGA (abiraterone acetate): Janssen
• NUBEQA (darolutamide): Bayer
• ERLEADA (apalutamide): Janssen
• PLUVICTO (lutetium-177 PSMA-617): Novartis
• AKEEGA (olaparib): Janssen Research & Development / Tesaro
• TALZENNA (talazoparib): Pfizer / Astellas Pharma
• LYNPARZA (olaparib): AstraZeneca / Merck
• RUBRACA (rucaparib): Clovis Oncology / Pfizer
• ARV-110 (bavdegalutamide): Arvinas
• MGC018 (vobramitamab duocarmazine): MacroGenics
• DS-7300 (genmaitamab): Daiichi Sankyo
• PSMA [Lu-177]-PNT2002: Point Biopharma
• Capivasertib: AstraZeneca
• EPI-7386: Essa Pharma

To know more about metastatic prostate cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

Metastatic Prostate Cancer Market Drivers

• Increasing prevalence of metastatic prostate cancer globally with approximately 8.2 million prostate cancer cases in the 7MM and rising incidence driven by rapidly aging population, particularly in developed markets
• Growth of pharmaceutical innovations addressing unmet medical needs with diverse therapeutic mechanisms including androgen receptor inhibitors, PARP inhibitors, radioligand therapies, and novel antibody-drug conjugates
• Extensive market penetration of approved therapies driven by label expansions, particularly XTANDI and NUBEQA expanding into mHSPC populations and earlier treatment lines
• Rising disease awareness and improved diagnostic capabilities enabling earlier identification of metastatic disease and initiation of treatment
• Development of companion diagnostics facilitating patient stratification based on biomarker status (BRCA mutations, AR mutations, PSMA expression)
• Paradigm shift toward triplet therapy in mHSPC (NUBEQA plus ADT and chemotherapy) establishing new standard of care and expanding market opportunity

Metastatic Prostate Cancer Market Barriers

• High cost of advanced therapies limiting patient access, particularly in emerging markets and among uninsured or underinsured populations
• Complex regulatory approval processes and lengthy clinical trial designs requiring multi-year development timelines
• Patent expiry of blockbuster therapies such as ZYTIGA creating pricing pressure for newer therapies targeting overlapping patient populations
• Variable patient response and resistance development due to heterogeneous disease biology and emerging resistance mechanisms
• Limited awareness and accessibility of newer therapies in certain geographic regions with lower healthcare infrastructure
• Significant side effects and tolerability concerns associated with systemic therapies affecting patient compliance and quality of life
• Reimbursement challenges and payer skepticism regarding cost-effectiveness of expensive radioligand therapies and emerging mechanisms despite clinical benefits

Scope of the Metastatic Prostate Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Metastatic Prostate Cancer Companies: Astellas Pharma, Janssen, Bayer, AstraZeneca, Pfizer, Novartis, Arvinas, MacroGenics, Daiichi Sankyo, Bristol Myers Squibb, Merck, Point Biopharma, Lantheus Holdings, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
• Key Metastatic Prostate Cancer Therapies: XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), NUBEQA (darolutamide), ERLEADA (apalutamide), PLUVICTO (lutetium-177 PSMA-617), AKEEGA (olaparib), TALZENNA (talazoparib), LYNPARZA (olaparib), RUBRACA (rucaparib), ARV-110 (bavdegalutamide), MGC018 (vobramitamab duocarmazine), DS-7300, and others
• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic prostate cancer current marketed and metastatic prostate cancer emerging therapies
• Metastatic Prostate Cancer Market Dynamics: Metastatic prostate cancer market drivers and metastatic prostate cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metastatic Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Prostate Cancer Market Access and Reimbursement

Discover more about therapies set to grab major metastatic prostate cancer market share @ Metastatic Prostate Cancer Treatment Market